Page last updated: 2024-09-03

celastrol and imatinib mesylate

celastrol has been researched along with imatinib mesylate in 2 studies

Compound Research Comparison

Studies (celastrol)	Trials (celastrol)	Recent Studies (post-2010) (celastrol)	Studies (imatinib mesylate)	Trials (imatinib mesylate)	Recent Studies (post-2010) (imatinib mesylate)
885	1	741	11,477	960	5,773

Protein Interaction Comparison

Protein	Taxonomy	celastrol (IC50)	imatinib mesylate (IC50)
Tyrosine-protein kinase ABL1	Homo sapiens (human)		0.31
Mast/stem cell growth factor receptor Kit	Homo sapiens (human)		0.1

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jin, Y; Lai, Y; Lu, Z; Pan, J; Qiu, L	1
Cao, Q; Chen, C; Jin, Y; Li, J; Lu, Z; Pan, J	1

Other Studies

2 other study(ies) available for celastrol and imatinib mesylate

Article	Year
Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer letters, 2010, Apr-28, Volume: 290, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; Pentacyclic Triterpenes; Piperazines; Pyrimidines; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays	2010
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Molecular cancer, 2010, May-19, Volume: 9 Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cell Separation; Child; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Middle Aged; NF-kappa B; Pentacyclic Triterpenes; Piperazines; Point Mutation; Pyrimidines; RNA, Small Interfering; Signal Transduction; Transcription, Genetic; Transfection; Triterpenes; Xenograft Model Antitumor Assays; Young Adult	2010

Article

Year

Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Cancer letters, 2010, Apr-28, Volume: 290, Issue:2

Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; Pentacyclic Triterpenes; Piperazines; Pyrimidines; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays

2010

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.

Molecular cancer, 2010, May-19, Volume: 9

Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cell Separation; Child; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Middle Aged; NF-kappa B; Pentacyclic Triterpenes; Piperazines; Point Mutation; Pyrimidines; RNA, Small Interfering; Signal Transduction; Transcription, Genetic; Transfection; Triterpenes; Xenograft Model Antitumor Assays; Young Adult

2010